Phase Ib Clinical Trial Recruiting Patients with Anaplastic Thyroid Cancer

For a Phase 1b clinical study of an orally administered study drug, PLX3397, targeting the cancer microenvironment, Plexxikon is currently recruiting patients with histologically or cytologically diagnosed anaplastic thyroid carcinoma.

Recent work has highlighted the role of a cell type known as Tumor-Associated Macrophages (TAMs) in the progression of thyroid cancers, and anaplastic thyroid carcinoma in particular is notable for abundant TAM infiltration. PLX3397 significantly reduces TAM levels, and in animal studies is associated with a significant reduction of tumor growth and metastatic spread.

The other Inclusion and Exclusion criteria for the Phase 1b study are typical and can be found on-line at Participating clinical sites are also listed.